Sanofi (NASDAQ:SNY) Shares Bought by Procyon Advisors LLC

Procyon Advisors LLC grew its stake in Sanofi (NASDAQ:SNY) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,441 shares of the company’s stock after acquiring an additional 277 shares during the quarter. Procyon Advisors LLC’s holdings in Sanofi were worth $552,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $29,000. Concord Wealth Partners boosted its holdings in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the last quarter. Fortitude Family Office LLC grew its stake in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after buying an additional 659 shares during the period. Sunbelt Securities Inc. increased its holdings in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the last quarter. Finally, Versant Capital Management Inc acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $54,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $50.74 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $128.77 billion, a P/E ratio of 25.89, a PEG ratio of 1.17 and a beta of 0.57. The firm’s 50-day moving average is $48.46 and its two-hundred day moving average is $52.09. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the business posted $2.55 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Sanofi will post 3.94 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.